The KAMRA™ Inlay Recieves FDA Approval
AcuFocus, Inc., the global leader in corneal inlay technology announced today that the United States Food and Drug Administration has approved its groundbreaking product, the KAMRA inlay. The KAMRA inlay is indicated to improve the near vision by extending depth of focus in presbyopic patients who have major emmetropic refractions (+0.50 D to -0.75 D). This approval represents the first major advancement in the surgical correction of presbyopia in well over a decade.
"The KARMA inlay is the number one implanted corneal inlay globally", said Just Mazzon, Chairman and CEO of AcuFocus, Inc. "After a decade of research, development and clinical investigation, we are delighted to bring this innovative technology to surgeons and patients in the U.S."
Go to AcuFocus.com to learn more!
Posted on Fri, April 17, 2015
by Sarah Hokuf